Summary of Purpose
The investigators plan to undertake a phase II study to investigate the efficacy and side effects of intravenous ketamine to reduce neuroexcitotoxicity, and thus provide neuroprotection in patients diagnosed with acute ischemic stroke.Read More →
The following dates are available for this trial. Trial information last updated on 2 February 2018.
|1 Apr 2018||14 Jul 2017||31 Mar 2019||31 Dec 2019||1 Feb 2018||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- Doylestown Health Lead
- Sudhir Aggarwal, MD, PhD